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Abstract Tegress is ethylene vinyl alcohol which is non-
allergenic and permanent. The aim of the study was to
evaluate efficacy, feasibility and safety of transurethral
Tegress® in women with urodynamic stress incontinence in
a two-centre setting. Approximately 33 female patients with
urodynamic stress incontinence were prospectively includ-
ed in the study. Preoperatively, the patient’s history,
gynaecological examination and multichannel urodynamics
were performed. On follow-up, the patient was asked to use
a visual analogue scale to measure her contentness and
underwent uroflowmetry and a cough test. Median follow
up was 51 months. About 15 women considered themselves
as completely continent, and 23 (69%) were either satisfied
or very satisfied. Pad test was positive in 18 (54.5%)
patients, and cough test was positive in 20 (60.6%).
Patients’ satisfaction did not correlate with objective
dryness. Ethylene vinyl alcohol is a bulking agent with a
success rate of approximately 45% after 51 months.
Introduction
When conservative therapy for stress urinary incontinence
fails, surgery is the mainstay of treatment. Urethral bulking
agents, as an office or day-case procedure, are the most
minimally invasive options available and are associated
with minimal morbidity.
According to a recent systematic review from the
Cochrane Database [1], injection therapy may represent a
useful option for short-term symptomatic relief amongst
selected women with co-morbidity that precludes anaesthesia.
Peri-urethral injectable agents have been used for the
treatment of urinary incontinence in women for more than a
century. A variety of substances have been used, the most
frequent being polytetrafluoroethylene (Teflon), polydimethyl-
siloxane elastomer (silicone), bovine glutaraldehyde cross
linked (GAX) collagen, carbon-coated zirconium beads,
hyaluronic acid/dextranomer and autologous tissues as fat
and cartilage [2–6]. Initially, Teflon injections were used but
were associated with migration, granuloma formation and
even carcinogenesis, and this material has now been
abandoned [15].
Collagen is one of the best-documented substances with
good initial success rates associated with an average of 1.5–2
injections [7–13] however, long-term success rates are not
satisfactory [14], with success rates as low as 26%.
The low success rates of collagen injections especially at
long-term follow-up have been attributed to collagenase-
induced biodegradation. Because of this, newer more durable
substances have been investigated to try and improve the
long-term outcome of injectable therapy. The other disad-
vantage of collagen is possible allergic reaction which occurs
in about 3%, and patients require an intradermal allergy test
at least 1 month prior to treatment [5].
Tegress® is ethylene vinyl alcohol, and within more than
150 publications, the substance has been successfully used
to treat cerebral aneurysms, carotid-cavernous fistulas and
esophagobronchial fistula in men [15–17]. It is a biocom-
patible polymer which is dissolved in an 8% dimethyl
sulfoxide (DMSO) carrier to allow injection of a very low-
viscosity fluid into tissue [17]. Once the material comes
into contact with body tissue or fluid, the DMSO rapidly
Int Urogynecol J (2008) 19:503–507
DOI 10.1007/s00192-007-0479-5
DO00479; No of Pages




A. Sohail :A. Monga
Princess Anne Hospital,
Southampton, UK
dissipates from the polymer, which results in a precipitate
of a coherent solid mass [17, 18] (Fig. 1). In contrast to
collagen, this substance is durable, not biodegradable and
non-allergenic. Animal studies in mini pigs demonstrated
that Tegress encapsulated with tissue in-growth into the
porous material structure, with no material migration to
other sites as determined by macro- and microscopic
specimen (Bard, data on file).
This study aimed to determine the feasibility and short-
and long-term efficacy of Tegress® injection for female
stress incontinence.
Materials and methods
Between September 1999 and October 2003, 33 female
patients with median age 69 (range 36–89) who were
referred to the urogynaecology outpatient clinic either to
Princess Anne Hospital, Southampton or to the urogynaecol-
ogy clinic, Frauenklinik, Inselspital Bern were included in
the study. Only women with urodynamic stress incontinence,
proper understanding of the local language, age >18 years
and safe contraception, who were not breast-feeding and
who gave written informed consent were included. Women
with more than stage 1 prolapse were excluded. Ethics
committee consent was obtained in both centres.
All patients were asked to fill in the Bristol female lower
urinary tract symptoms questionnaire (BFLUTS) [19] and
to estimate their grade of satisfaction on a visual analogue
scale of 1 to 10. A grade of 0–3 was considered not satisfied,
4–7 moderately satisfied and more than 8 as satisfied.
BFLUTS is a questionnaire, which is divided into the
three domains voiding disorders, urinary incontinence and
overactive bladder (OAB) symptoms. The severity of
symptoms is divided in columns.
“I have this problem never, occasionally, sometimes,
most of the time or always”. We rated the problem as being
present with at least sometimes being bothersome in at least
50% of the specific questions.
A complete history, clinical gynaecological examination
to assess prolapse and a cough and pad test were performed.
For the cough test, the patients were asked to cough in the
upright position at bladder capacity to visualize leakage. Any
visual leakage was noted as positive cough test.
A 45-min pad test was performed according to International
Continence Society (ICS) recommendations and was consid-
ered positive if the difference in pad weighing before and after
the test was 2 g or more.
Urodynamic investigations were done prior to surgery.
Cystometry was performed in the sitting position with the
patient in the 45° upright position with a six French
microtip transducer, which was introduced into the bladder
for intravesical pressure measurement, and a water-perfused
balloon catheter was introduced into the rectum for intra-
abdominal pressure measurement. Bladder was filled with a
rate of 20 ml/min with saline solution at 37°. Filling was
continued until the patient experienced a strong desire to
void. A cough stress test was performed every 100 ml of
filling. At bladder capacity, pressure-flow studies were
performed. Urethra pressure profile was performed at rest
three times repetitively and the maximum urethra closing
pressure (MUCP) und functional urethral length (FUL).
At final follow-up, all women completed the BFLUTS
questionnaire and a visual analogue scale and underwent
uroflowmetry and cough test at bladder capacity. Residual
urine was measured using abdominal post-void ultrasound.
Tegress® can be stored at room temperature. At
contact with moisture, it forms a spongy non-absorbable
mass (Fig. 1). Due to low viscosity, the material is easily
injected, and it has no allergenic potential.
Injection was performed transurethrally under cystoscopic
view. For injection, the patient was placed in lithotomy
position. Cystoscopy using a 20° optic was performed prior
to and during injection to visualize coaptation of the bladder
neck. Approximately 1 ml was injected per injection site
very slowly over 60 s; after injection, the needle remained in
place for a further 60 s before it was withdrawn, twisting the
needle to allow easy disconnection between the needle and
the material. This allows the material to precipitate in contact
with body fluids and prevents extravasation. The substance
was injected at the four and eight o’clock positions, with a
maximum total amount of 2 ml per session by two different
surgeons (AK, AM) who were using exactly the same
technique.
Patients were considered cured if there was no subjective
or objective evidence of stress incontinence. Success was
defined as subjective and objective improvement of stress
incontinence, whereas failure was no change or worsening
of symptoms.
Fig. 1 Detailed view of Tegress®
504 Int Urogynecol J (2008) 19:503–507
Statistics were performed using the InStat system
version 4.0 for Windows. To test whether the median of
the variable flow and residual urine differs between the two
groups pre- and post-operatively, t test was used.
Results
Median follow-up was 51 months (range 35–68 months).
Twenty-nine patients had a history of previous surgery for
stress incontinence and/or gynaecologic surgery (Table 1).
All patients had urodynamically proven stress incontinence
(Table 2).
Twenty-four patients had one injection, while 9 patients
(27.2%) required a second injection which was performed
6 weeks after the initial treatment. Table 3 demonstrates
subjective and objective cure rates, and Table 4 shows the
results of the BFLUTS questionnaire pre- and post-
operatively.
Fifteen women (45%) reported themselves as completely
continent, and 23 (69%) were either satisfied or very happy.
Flow rate and residual urine did not differ significantly
pre- and post-operatively (p=0.99, two-tailed t test) with
flow rates of 32 ml (range 27–43) preoperatively and 30 ml
(range 26–39) post-operatively. Both groups followed a
Gaussian distribution.
The only post-operative complications were voiding
difficulties or persistent stress incontinence. Voiding diffi-
culties lasted for 1 day only and occurred in two patients;
no patient suffered from long-term problems.
Discussion
To our knowledge, this is the first study of ethylene vinyl
alcohol with long-term data. The subjective and objective
cure rates were approximately 42%, and the patients’
satisfaction reached 69% (visual analogue scale ≥4) which
is comparable to Tamanini et al. [20], who demonstrated a
73% improvement/cure rate in 15 patients 60 months after
Macroplastique® injection.
A multi-centre randomized study from the USA [21]
showed a rate of 59% successfully treated patients defined
by a negative pad test and a 59% dry and improved rate
using the Stamey grade. In this study, 253 women were
included, and follow-up was 12 months. Compared to our
data, we can assume a slight decrease in continence of
approximately 10% over the next 4 years. Most other
studies with a short-term follow-up only of 12–24 months
have slightly better results with success rates of 67–94%.
The only study with long-term follow-up of more than
5 years showed a success rate of 26% [14]. In this study,
collagen was applied peri-urethrally.
Another study [22] found 62% dryness after bulking
agents with a follow-up of 32 months. However, this is a
rather difficult comparison as those patients were injected
Table 2 Urodynamics prior to surgery
Urodynamic
findings
Bladder capacity (median, range) 312 (289–428)
First sensation to void (median, range) 188 (136–289)
Second sensation to void (median, range) 260 (212–310)
Detrusor pressure at maximum flow rate cm H2O
(median, range)
28 (12–30)
MUCP cm H2o (median, range) 28 (12–31)
FUL mm (median, range) 23 (17–27)
Positive cough test n 33
Maximum flow rate (median, range) 32 (27–43)
Table 3 Cure rates and success
Number of patients %
Objective cure
Pad test negative 15 45.5
Cough test negative 13 39.4
Subjective cure




8 or more 5 15
Cured overall 14 42.4
Success overall 18 54.4
Table 1 Previous surgery for stress incontinence and general
gynaecologic surgery; some patients had more than one operation
All patients (n=33)
Marshall Marchetti Burch 9
Pereyra needle suspension 8











Pre-operatively 2 12 33
Post-operatively 2 9 8
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after radical prostatectomy, and various bulking agents as
collagen, silicone and hyaluronidase acid were used.
Technically, Tegress® is slightly more difficult to apply
because the injection rate should be very slow to allow the
substance to have adequate contact with the tissue and
establish the spongy mass [17]. Safety of the substance,
particularly the lack of a significant fibrotic response, has
been demonstrated in animal studies [18], and this is
undermined if we consider the few cystoscopy results of
those study patients who required cystoscopy during the
tension-free vaginal tape (TVT) procedure. In a recently
published study [24], there was a concern about the safety
of ethylene vinyl alcohol, as an erosion rate of 37% was
noted. However, in this retrospective study of 19 patients,
the recommendation of the amount of 1 ml ethylene vinyl
alcohol per site was not respected, and injection was
performed due to the degree of coaptation, which is not
necessary according to the producer’s recommendation.
Another study by Erekson et al. [25] has presented some
significant local complication of ethylene vinyl alcohol in
two patients. Urethral erosion is a very serious complica-
tion, which has to be considered particularly when there is a
deterioration of incontinence post-operatively or recurrent
urinary tract infections occur. This is a severe potential
downside of permanent urethral bulking agents, and the
patient has to be informed about this complication prior to
surgery. Removal of a permanent mass requires another
intervention and may deteriorate continence, leaving
urethral scar tissue behind resulting in a drainpipe urethra.
Since initial injections, two patients have undergone a TVT
for persistent urodynamic stress incontinence. At cystosco-
py during the TVT procedure, no Tegress was visible inside
the bladder or urethra.
All other patients requested no further treatment,
although some of them were not completely dry.
The risks of permanent injectables as ethylene vinyl
alcohol in stress-incontinent women have to be weighed
against the short life of non-permanent materials like collagen.
Overall complication rate in our series is very low, mainly
consisting of retention or persistent stress incontinence.
Peri-operative complications associated with peri-urethral
injections are uncommon; transient urinary retention is
approximately observed in 15% of patients [13] which was
similar in our patients.
During injection, perforation and extravasation of the
injected material can occur if the mucosa is disrupted. With
both substances, this was generally not a problem because
collagen is immediately flushed away and Tegress can
easily be removed by the injection needle or the cystoscope.
Some authors report discomfort during the injection [7]
but we did not experience this side effect during our study.
This may be due to the transurethral injection technique in
comparison to peri-urethral application.
It remains difficult to compare results of treatment for
stress incontinence, as many authors do not differentiate
between subjective and objective or between cure and
success. In our series, we have a cure rate of 42% and a
54.4% success rate. Two patients still required further
surgery despite improvement of symptoms. The decision
about further surgery was based on the patients’ wishes.
The cure rate may not seem excellent; however, when
applying similar criteria, Ward et al. [26] found a 60% cure
rate following TVT and Burch in patients with primary
stress incontinence. These results were approximately 30%
lower than the 5-year results published by Ulmsten et al.
[27]. This is most likely attributable to the fact that all
surgery was performed by one surgeon but also to the fact
that there were no objective criteria to determine cure, and
cure and success was not differentiated.
A weakness of the study is that we used our own scoring
system for the BFLUTS questionnaire. As we qualified the
bladder problems as such if the questions were at least
positive in 50% starting from “sometimes a problem”, we
do not take the bothersomeness of occasional occurrence
into account. However, to our knowledge, there is no
published scoring system available which could be used.
A recent publication suggests the Symptom Severity
Index and Symptom Impact Index (SSI/SII) as best patient-
based outcome measures to assess urinary incontinence [28].
It must be recognized that in this group of negatively
selected patients, success rates of other forms of treatment
may well be comparable. It should also be taken into
consideration that in general, transurethral injections can be
applied under local anaesthesia, whereas other techniques
are not only more invasive with a higher complication rate
but often also require general anaesthesia. Success rates for
recurrent urinary incontinence with intrinsic sphincter
deficiency (ISD) are around 70% for TVT and Burch
colposuspension which is slightly better; however, compli-
cation rates are noticeably higher.
In conclusion, ethylene vinyl alcohol copolymer is a
permanent bulking agent with a patient satisfaction rate of
69% and a cure rate of 40% in women with urodynamic
stress incontinence after 51 months follow-up. Despite the
absence of urethral erosions in our series, we need to be
cautious about this serious side effect in permanent bulking
agents, and patients should be informed about this.
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